{"id":212,"date":"2026-04-11T09:32:53","date_gmt":"2026-04-11T09:32:53","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=212"},"modified":"2026-09-30T09:01:13","modified_gmt":"2026-09-30T09:01:13","slug":"lucilaro-larotrectinib","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/fr\/product\/lucilaro-larotrectinib\/","title":{"rendered":"\u00a0LuciLaro"},"content":{"rendered":"

HIGHLIGHTS OF PRESCRIBING INFORMATION <\/strong><\/span><\/p>\n

These highlights do not include all the information needed to use LuciLaro safely and effectively. See full prescribing information for LuciLaro.<\/strong><\/span><\/p>\n

 <\/strong><\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LuciLaro is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:<\/span><\/p>\n

\u2022 have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, <\/span><\/p>\n

\u2022 are metastatic or where surgical resection is likely to result in severe morbidity, and <\/span><\/p>\n

\u2022 have no satisfactory alternative treatments or that have progressed following treatment.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION<\/strong><\/strong><\/span><\/p>\n

\u2022 Select patients for treatment with LuciLaro based on the presence of a NTRK gene fusion.<\/span><\/p>\n

\u2022 Recommended Dosage in Adult and Pediatric Patients with Body Surface Area of at Least 1.0 Meter-Squared: 100 mg orally twice daily.<\/span><\/p>\n

\u2022 Recommended Dosage in Pediatric Patients with Body Surface Area of Less Than 1.0 Meter-Squared: 100 mg\/m2 orally twice daily.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS <\/strong><\/strong><\/span><\/p>\n

Capsules: 100mg\u00d730 capsules<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS <\/strong><\/strong><\/span><\/p>\n

None.<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Neurotoxicity: Advise patients and caretakers of the risk of neurologic adverse reactions. Advise patients not to drive or operate hazardousmachinery if experiencing neurotoxicity. Withhold and modify dosage, or permanently discontinue LuciLaro based on severity. <\/span><\/p>\n

\u2022 Hepatotoxicity: Monitor liver tests including ALT and AST every 2 weeksduring the first month of treatment, then monthly thereafter and as clinically indicated. Withhold and modify dosage, or permanently discontinue LuciLaro based on severity. <\/span><\/p>\n

\u2022 Embryo-Fetal Toxicity: Can cause fetal harm. Advise females with reproductive potential of potential risk to the fetus and to use effective contraception. <\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS <\/strong><\/strong><\/span><\/p>\n

The most common adverse reactions (\u2265 20%) with LuciLaro were fatigue, nausea, dizziness, vomiting, increased AST, cough, increased ALT, constipation, and diarrhea.<\/span><\/p>\n

 <\/span><\/p>\n

DRUG INTERACTIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Strong CYP3A4 Inhibitors: Avoid coadministration of strong CYP3A4inhibitors with LuciLaro. If coadministration cannot be avoided, reduce the LuciLaro dose. <\/span><\/p>\n

\u2022 Strong CYP3A4 Inducers: Avoid coadministration of strong CYP3A4inducers with LuciLaro. If coadministration cannot be avoided, increase the LuciLaro dose. <\/span><\/p>\n

\u2022 Sensitive CYP3A4 Substrates: Avoid coadministration of sensitive CYP3A4 substrates with LuciLaro. <\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS <\/strong><\/strong><\/span><\/p>\n

\u2022 Lactation: Advise not to breastfeed. <\/span><\/p>\n

\u2022 Hepatic Impairment: Reduce the starting dose of LuciLaro in patients with moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment. <\/span><\/p>\n

 <\/span><\/p>\n

Storage <\/strong><\/strong><\/span><\/p>\n

Store at 20\u2103 to 25\u2103 (68\u2109 to 77\u2109), excursions permitted between 15\u2103 and 30\u2103 (59\u2109 and 86\u2109) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciLaro contains larotrectinib and is supplied as oral capsules. Please confirm the prescribed strength and review the full product information before ordering. A valid prescription and identity verification are required.<\/p>","protected":false},"featured_media":2065,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[40],"product_tag":[],"class_list":["post-212","product","type-product","status-publish","has-post-thumbnail","product_cat-broad-spectrum-cancer","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product\/212","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/comments?post=212"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/media\/2065"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/media?parent=212"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_brand?post=212"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_cat?post=212"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/fr\/wp-json\/wp\/v2\/product_tag?post=212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}